ArticleClinical & experimental metastasis2011
Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.
Article in Clinical & experimental metastasis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Human Cyclophilins-An Emerging Class of Drug Targets.Medicinal research reviews · 2026Review
- Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq.Discover oncology · 2025Article
- Proteome-Wide Discovery of Cortical Proteins That May Provide Motor Resilience to Offset the Negative Effects of Pathologies in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability.Oncogene · 2020Article
- Functional Annotation of ABHD14B, an Orphan Serine Hydrolase Enzyme.Biochemistry · 2020Article
- OSlgg: An Online Prognostic Biomarker Analysis Tool for Low-Grade Glioma.Frontiers in oncology · 2020Article
- Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.Annals of translational medicine · 2018Review
- Sequence analysis and structure prediction of ABHD16A and the roles of the ABHD family members in human disease.Open biology · 2018Review
- Management of neuroendocrine tumors of unknown primary.Reviews in endocrine & metabolic disorders · 2017Review
- Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.Clinical & experimental metastasis · 2014Article
- The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm.Clinical & experimental metastasis · 2014Article
- Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors.BMC genomics · 2014Article
- New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.PloS one · 2014Article
- Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.Annals of surgical oncology · 2013Article
- Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism.Biochimica et biophysica acta · 2013Review
- Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.Surgery · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A characteristic of human gastroenteropancreatic neuroendocrine tumors (GEP-NET) is a minute unobtrusive primary tumor which often cannot be detected by common physical examinations. It therefore remains unidentified until the tumor has spread and space-occupying metastases cause clinical symptoms leading to diagnosis. Cases in which the primary cannot be located are referred to as NET with CUP-syndrome (cancer of unknown primary syndrome). With the help of array-CGH (comparative genomic hybridization, Agilent 105K) and gene expression analysis (Agilent 44K), microdissected primaries and their metastases were compared to identify up- and down-regulated genes which can be used as a marker for tumor progression. In a next analysis step, a hierarchical clustering of 41.078 genes revealed three genes [C-type lectin domain family 13 member A (CD302), peptidylprolyl isomerase containing WD40 repeat (PPWD1) and abhydrolase domain containing 14B (ABHD14B)] which expression levels can categorize the metastases into three groups depending on the localization of their primary. Because cancer therapy is dependent on the localization of the primary, the gene expression level of these three genes are promising markers to unravel the CUP syndrome in NET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.